Neuroscience Expansion

Strategically, the fenebrutinib data reinforce Roche’s plan to broaden its neuroscience portfolio as Ocrevus approaches patent expiry in the coming decade. A first‑in‑class BTK inhibitor that could occupy the high‑efficacy oral niche in both relapsing MS and primary progressive MS would be a key growth driver for the pharmaceutical segment. Ens­pryng’s MOGAD results position Roche as the potential pioneer treatment for this rare disease, expanding its impact across the broader neurology field.